首届国际药学院校发展论坛会议议程

新媒体中心中国药科大学 2019-05-25

一、会议概况PART/01

　　为了顺应瞬息万变的世界和不断发展的医药卫生领域，我校将于2018年11月16日9:00-20:00在江宁校区大礼堂举办“首届国际药学院校发展论坛”。本次论坛由国际合作与交流处、药学院共同承办。论坛邀请包括美国密西根大学、美国明尼苏达大学、澳大利亚莫纳什大学、英国伦敦大学学院、荷兰莱顿大学、日本京都药科大学、韩国国立首尔大学、香港中文大学、澳门科技大学、浙江大学、复旦大学、四川大学、沈阳药科大学、中山大学、华中科技大学等众多国内外知名院校药学院40余位院长，共同探讨药学教育全球化趋势，共商药学院校未来发展的机遇及挑战。

　　本次论坛的主题是“药学院校的科学研究与药学教育”，主要议题包括：

　　1、药学学科前沿发展动态及药物研发过程中学科合作与创新机制探索

　　2、药学院课程设置与教学模式创新

　　3、药学院校的管理模式创新

　　4、学术研究与医药产业的合作

二、会议议程PART/02

三、特邀嘉宾名单PART/03

四、特邀报告嘉宾简介PART/04

James T. Dalton, Ph.D.

Dean, School of Pharmacy, University of Michigan, USA

James T. Dalton, Ph.D. is Dean and Professor of Pharmaceutical Sciences in the College of Pharmacy at the University of Michigan. He received his BS in Pharmacy from the University of Cincinnati (1986) and PhD in pharmaceutics from Ohio State University (1990). Dean Dalton rose through the faculty ranks in the Department of Pharmaceutical Sciences at the University of Tennessee (1992-2000) before returning to Ohio State where he served as Professor and Chair in the Division of Pharmaceutics (2000-2007). He began an entrepreneurial leave of absence from Ohio State in 2005 and left OSU in 2007 to devote his full-time effort as Chief Scientific Officer at GTx, Inc. (2007-2014) where he oversaw the preclinical and clinical development of selective androgen receptor modulators. Dean Dalton has actively engaged in teaching, research, and service to the pharmacy profession throughout his education and career. He is a Fellow of the American Association for the Advancement of Science (AAAS) and American Association of Pharmaceutical Scientists (AAPS). He has co-authored over 300 original abstracts and peer-reviewed scientific manuscripts and is an inventor on over 400 United States and international patent applications related to drug discovery and development.

Maode Lai MD.

President, China Pharmaceutical University, CHINA

Professor Maode Lai graduated from the Department of Medicine of Zhejiang Medical University in 1982. He received his MS degree in medicine from Zhejiang Medical University in 1987 and his MD degree from Luebeck Medical University in Germany in 1990. He became professor in 1994. He has been the adjunct professor of the University of Alberta in Canada since 2010. He was selected as a member of German National Academy of Sciences Leopoldina in 2011. He became vice-president of Zhejiang Medical University in 1996 and vice-president of Zhejiang University in 1998. He has been the president of China Pharmaceutical University since 2013.

Previous academic positions and titles include: Chairman of Chinese Society of Pathology (the 10th Committee), Vice President of the 1st and 2nd Committee of the Chinese Association of Pathologists, Vice-Chairman of the National Teaching & Research Association of Higher Educational Institutions, and Vice-Chairman of the National (Ministry of Education) Supervising Committee of Basic Medicine Education. Executive Editor of “Pathology - Research and Practice”, Associate Editor-in-Chief of “Chinese Journal of Pathology”, “Clinical & Experimental Pathology”, etc.
Research specialty: Pathology of colorectal cancer. PIs of several national key research projects.
Prizes and honors include: 2 first prizes of Zhejiang Provincial Science & Technology Progress Award, 3 second prizes of the National Outstanding Educational Achievements Award, Teaching Excellence in National-Level Key Course of “Pathology” and the Teaching Team at Zhejiang University, National Outstanding Teacher, the State Educational Commission Fok Ying Tung Outstanding University Young Teacher and Super Expert of Zhejiang Province.

Bill Charman

Dean, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, AUSTRALIA

Bill is Dean of the Faculty of Pharmacy and Pharmaceutical Sciences and Chair of the International Pharmaceutical Federation Education Executive Committee in The Hague, The Netherlands. He was the founding Director of the Monash Institute of Pharmaceutical Sciences from 2007 through 2017.

The average annual QS World University rankings for 2012-2017 (in the pharmacy and pharmacology discipline) rank Monash University as the number one program in Australia, the number one program in the AsiaPacific, and top ten worldwide. In 2017, Monash was ranked number two worldwide.

Bill’s research has been characterised by a multidisciplinary and collaborative approach to address major issues in drug discovery (especially for neglected diseases such as malaria), drug delivery and the pharmaceutical sciences. He has published more than 370 scientific papers and communications and given over 190 invited national and international presentations. He has received numerous national and international awards for his research and received various fellowships from international professional associations.

Previously, he was Chairman of the Wellcome Trust Seeding Drug Discovery Funding Committee; a member of the Expert Scientific Advisory Committee of the Medicines for Malaria Venture; an advisor to the World Health Organisation; and a Chair/member of Scientific Advisory Boards and two Corporate Boards.

Duncan Q.M.Craig

Director, School of Pharmacy, University College London, UK

Duncan graduated from the University of Bath in 1984 with a first class BPharm and, following pre-registration training at Upjohn Ltd and St Thomas' Hospital, he went on to study for a PhD at the School of Pharmacy, University of London, on the topic of polymeric drug delivery systems. He subsequently joined the staff and rose to the position of Reader in 1999 but left to take up a chair at the Queen's University Belfast, where he stayed for four years before moving to the University of East Anglia to set up the new School of Pharmacy in 2003. The School went on to achieve top ranking in the national student survey for five years in a row and was consistently ranked within the top 3 UK pharmacy schools in the major league tables under his stewardship. He stepped down as Head of School in 2011 to work for the Vice-Chancellor's Office as Director of Internationalisation, charged with shaping the university's policy on international relations and collaborations. In 2013 he returned to the School of Pharmacy, now part of UCL, to assume the position of Director of the newly merged School. Duncan has won numerous prizes including the Glaxo SmithKline International Award, the Controlled Release Society Young Investigator Award and the British Pharmaceutical Conference Science Award.

Hubertus Irth

Scientific Director/professor, Leiden Academic Centre for Drug Research

University of Leiden, NETHERLANDS

Since September 1, 2016, Hubertus Irth is scientific director of the LACDR and a full professor in Biomolecular Analysis. His main research interest lies in the development of analytical screening technologies based on the integration of chemicalanalysis and biological screening.

He contributed more than 150 research papers and several patents to this field, many in coauthorship with colleagues from a wide variety of disciplines. In 1997, he started Screentec(later Kiadis Pharma) as a spin-off company from Leiden University. In 2005 he returned full time to academia, after having served as CEO and CSO in a highly dynamic biotech company
After becoming full professor at Vrije Universiteit Amsterdam, he was involved in several industrial, EU and Top Institute Pharma projects in the area of toxicologyand medicinal chemistry. From 2004-2006 and in 2009, he served as scientific director of the Department of Chemistry & Pharmaceutical Sciences.

Hewas cofounder of the Amsterdam Institute for Molecules, Medicines and Systems (AIMMS), an interdisciplinary institute in the area of drug research. He is one of the initiators of a novel Bachelor education program, Science, Business & Innovation,that bridges the disciplines of pharmaceutical sciences and business.
In 2010, he became Dean of the Faculty of Sciences at Vrije Universiteit Amsterdam, later also of the Faculty of Earth & Life Sciences. While serving at the Faculty board at Vrije Universiteit Amsterdam for six years, he was responsible for initiating and implementing a strategic collaboration between the science faculties of VUAmsterdam and the University of Amsterdam as well as a close collaboration withthe VU Medical Center. During his deanship, he was serving in the board of several academic institutions and research institutes.

Lynda Welage, Pharm.D. , FCCP

Dean and Professor

College of Pharmacy

University of Minnesota, US

Dr. Welage was appointed Dean and Professor of the University of Minnesota College of Pharmacy in July 2017.

Dr. Welage received her B.S. in pharmacy from the University of Michigan and her Doctor of Pharmacy (Pharm.D.) degree from the State University of New York at Buffalo. Subsequently, she completed a post-doctoral fellowship at the Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital in Buffalo, New York, and then became program director for critical care research at the same institution.

In 1988, she joined the faculty at the University of Michigan where she rose through the academic ranks. At the University of Michigan, College of Pharmacy she served as Associate Dean for Academic Affairs from 2004-2011. In addition, she served as an Associate Director in the Michigan Institute for Clinical and Health Research overseeing education and career development activities for translational research from 2009-2011.

In 2011, she transitioned to the University of New Mexico where she served as Dean and Professor of the College of Pharmacy until joining the University of Minnesota.

Dr. Welage’s area of emphasis was in critical care focusing on pharmacotherapeutic challenges in trauma and burn victims. Her past research focused on alterations in drug disposition in critically ill patients and enhancing pharmacotherapeutic outcomes. Recent research efforts have focused on addressing concerns related to health care workforce. She has published extensively in the area of critical care and evidence based pharmacotherapy and has also served as a grant reviewer for several organizations.

Dr. Welage has been an active participant in local, state and national pharmacy and medical organizations, and is a fellow of the American College of Clinical Pharmacy. She currently serves on the Board of Trustees for the American College of Clinical Pharmacy Research Institute.

Ken-Ichi Inui, Ph.D.

President, Japan Society for Pharmaceutical Education;

Professor Emeritus, Kyoto Pharmaceutical University, JAPAN

Dr. Ken-ichi Inui had been appointed as the President of Kyoto Pharmaceutical University since 2010, and contributed to establish new pharmaceutical education system of 6-year program, and stepped down in 2016. Dr. Inui has been appointed as Professor Emeritus and Visiting Professor of Kyoto Pharmaceutical University. He received his B.S. (1969), M.S. (1971) and Ph.D. (1977) in Pharmaceutical Sciences from Kyoto University. Dr. Inui worked at Harvard Medical School, Massachusetts General Hospital (1978-1979) and Department of Pharmacy, Kyoto University Hospital (1979-1990). He was appointed as Professor and Director, Department of Hospital Pharmacy, Tokyo Medical and Dental University (1990-1993), returned to Kyoto University Hospital as Professor and Director in 1994, and retired Kyoto University in 2010. Dr. Inui has been appointed as Professor Emeritus of Kyoto University in 2010.

His research interests include (1) functional and molecular characterization of drug transporters and clinical application, (2) pathophysiological roles of drug transporters and mechanisms of drug interaction, (3) pharmacogenomics and personalized medicine. He has conducted excellent research on drug transporters in the small intestine, kidney, and liver to clarify the molecular mechanisms of the pharmacokinetics of drugs and clinical application, the so-called “From Bench to Bedside”. Dr. Inui was the recipient of the Japanese Society for the Study of Xenobiotics Award in 2002, the Pharmaceutical Society of Japan Award in 2006, the Academy of Pharmaceutical Science and Tecnology, Japan and the AAPS Research Achievement Award in Pharmacokinetics, Pharmacodynamics and Drug Metabolism in 2008. Dr. Inui is the author or co-author of more than 350 original articles and 20 reviews in peer-reviewed journals, and has edited or contributed chapters to 13 books, with the total citations of 16,701 (as of October 2018 by Scopus, h-index:70). Dr. Inui has been serving as an Associate Editor for Pharmacology and Therapeutics, and a member of the Editorial Advisory Board for Biochemical Pharmacology.

Minsoo Noh, Ph.D.

Associate Dean, Student Affairs

Associate Professor

College of Pharmacy

Natural Products Research Institute

Seoul National University, KORE

Minsoo Noh received the B.S. degree in pharmacy from Seoul National University and have a pharmacist license in Korea. He received the Ph.D. degree in the field of systems toxicology and pharmacology from Massachusetts Institute of Technology, USA. As one of his professional carrier, he had been worked in the Drug Discovery Division, Bioscience Division and Skin Research Division of Amorepacific Corporation, Korea until 2010. He is actively participating in Korean Society for Applied Pharmacology (KSAP) and working as editor-in-chief for Biomolecules & Therapeutics, the official journal of KSAP. He is working at the College of Pharmacy in Seoul National University as an Associate Professor and currently serving as the Associated Dean for Students Affairs.

Michael Coughtrie

Dean, Faculty of Pharmaceutical Sciences

University of British Columbia, CANADA

Dr. Michael Coughtrie is professor and dean at the Faculty of Pharmaceutical Sciences at the University of British Columbia (UBC). Born in Glasgow, Scotland, he received his BSc in biochemistry in 1983 and PhD in 1986 from the University of Dundee where he also began his professional teaching and research career based in the School of Medicine there. In 2003, Dr. Coughtrie was awarded a Personal Chair in Biochemical Pharmacology and became head of the Division of Pathology and Neuroscience. In 2008, he assumed the role of director, Division of Medical Sciences and in 2011 he accepted the appointment of operations director of the Medical Research Institute.

Dr. Coughtrie commenced his term as dean of the UBC Faculty of Pharmaceutical Sciences on August 1, 2013. His extensive teaching experience encompasses the development and implementation of a number of course modules in the fields of medicine, dentistry and science. As a researcher focusing on the roles of two major families of drug metabolizing enzymes, he has supervised numerous PhD and postdoctoral students, been invited to speak at over 70 international meetings and conferences, and has received more than 70 competitive research grants and contracts. In addition, Dean Coughtrie is an accomplished author, having written more than 200 papers, articles, book chapters, and abstracts appearing in publications such asThe Biochemical Journal, The New England Journal of Medicine, The Journal of Biological Chemistry and Drug Metabolism & Disposition.

Throughout his career, Dr. Coughtrie has volunteered his significant senior management experience and passion for the pharmaceutical sciences to a number of different boards, committees and professional associations and serves on the editorial boards of publications including Pharmacogenetics & Genomics, Xenobiotica and Biomarkers.

PAOLO CALICETI

Head, Department of Pharmaceutical and Pharmacological Sciences

University of Padova, ITALY

Received his Master in Pharmaceutical Chemistry and Technology in 1984 and the PhD in Pharmaceutical Sciences at University of Padova in 1989. Since 1989, he has worked at the University of Padova as assistant and associate professor and since 2002 he is Full Professor in Pharmaceutical Technology. He has worked as invited scientist at NIH (Bethesda, USA,1986/1987), Academy of Sciences of Moscow (1990) and SK&B, (PA,USA 1994).

His scientific interest is focused on the design and development of innovative supramolecular and multifunctional nanocarriers for the delivery. The ongoing projects include:

Chemical and physical modification of bioactive peptides and proteins with soluble polymers, namely PEGylation;
Polymer therapeutics, bioconjugates for active targeting
Lipid and polymeric biodegradable nano-/micro-particles for controlled protein and small drug delivery by supercritical techniques;
New cyclodextrin based drug carriers;
Novel oligonucleotide delivery systems
Decorated gold nanoparticles for drug delivery
Smart liposomes

He has been co-authors of more than 150 publications and 17 patents. He served as evaluator for grant applications in Italy, several countries and for EU committees. He has being consultant for international pharmaceutical companies. He is member of editorial board of a few scientific journals. He is associate editor for the Journal Controlled Release He is member of the steering committee of national scientific societies, including Division of Pharmaceutical technology of Italian Chemical Society, ADRITELF and Controlled Release Society Italian Chapter (president from 2008 to 2014)

Prof Jay S. Siegel

Dean, Health Science Platform,

Tianjin University, CHINA

Jay S. Siegel received his Ph. D. from Princeton (1985), was a Swiss Universities Fellow at ETH Zurich (1983-4), and NSF-CNRS postdoctoral fellow at the University of Louis Pasteur in Strasbourg (1985-6). He began as Assistant Professor of Chemistry (1986) at UCSD, was promoted to Associate Professor (1992) and Full Professor (1996). In 2003, he was appointed as Professor and co- director of the Organic chemistry institute of the University of Zurich (UZH) and Director of its laboratory for process chemistry research (LPF). He served as Dean of Studies and Head of the Research Council for the Faculty of Sciences at UZH. He moved to Tianjin University in 2013 and joined the Schools of Pharmaceutical and Life Sciences into a new Health Science Platform. He was Qianren Scholar (2013-15) and recipient of the Chinese National Friendship Medal (2015). He was named one of the 40 most influential foreign experts in China's 40 years of opening (2018). Prof. Siegel was a US-NSF Presidential Young Investigator (1988), an American Cancer Society Jr. Fellow (1990), an Alfred P. Sloan Fellow (1992), and an Arthur C. Cope Scholar by the ACS (1998). He was elected fellow of the American Association for the Advancement of Science (1998), fellow of Royal Society of Chemistry (2007) and fellow of the American Chemical Society (2018), and Alexander von Humboldt Research Award fellow (2018). He was visiting professor at Princeton, Caltech, University of Basel, the Weizmann Institute and Tokyo Institute of Technology. He has served on numerous society, foundation and journal advisory boards often as president. He has run grant panels and award programs for the US-NSF, EU-ERC, ARES and IUF- France, KAUST-Saudi Arabia, RGC-Hong Kong, FWF-Austria, and SNF-Switzerland. His research focuses on molecular design & synthesis, specializing in structural chemistry and stereochemistry of supramolecular architectures. (H-index 60; cit. 12 K – Google scholar // H-index 52; cit. 10 K – ISI).

ZUO Zhong, Joan

BSc, PhD

Director and Professor

School of Pharmacy, Faculty of Medicine,

The Chinese University of Hong Kong, CHINA

Professor Joan Zuo is the Director and Professor of the School of Pharmacy at the Chinese University of Hong Kong. She holds a B. Sc. and a Ph.D. in Pharmaceutical Sciences and has had over 20 years’ experience in the biopharmaceutics and pharmacokinetics fields. Since she joined the School of Pharmacy at the Chinese University of Hong Kong in Jan 2000, Prof. Zuo has secured over 10 million continuous supports from various grant agencies such as University Grant Council, Innovation Technology Foundation, Food and Health Bureau, Hospital Authority in Hong Kong SAR as PI to support her series investigations on bioactive herbal components. The mechanistic findings on the absorption and metabolism of these components have been applied to areas such as in vitroand in vivo quality control of herbal products, improvement in delivery of herbal components in vivo, elucidation or even prediction of potential herb/herb or herb/drug interactions in vivo. Prof. Zuo’s research findings in the above fields have generated over 200 original research and conference papers and patents of USA, China, Hong Kong and Malaysia. Currently, Prof. Zuo is serving as editorial board member for Biopharmaceutics and Drug Dispositions, Xenobiotica and grant reviewer for China and Macau, and journal reviewer for more than 50 international peer reviewed journals. In 2011, Prof. Zuo was elected to be the member of Nomination Committee of the International Society of Xenobiotics (ISSX) aiming to promote excellent xenobiotics research/researchers in the Asia Pacific region.

Yizhun Zhu

Dean, School of Pharmacy

Macau University of Science and Technology, CHINA

Dr. Yi Zhun Zhu is a Chair Professor of Pharmacology and dean of School of Pharmacy, Macau University of Science and Technology. Dr. Zhu got his Bachelor of Medicine at Shanghai Jiaotong University in 1989 and M.D./Ph.D. from Faculty of Medicine, University of Heidelberg, Germany in 1995. He joined as a faculty member of the Department of Pharmacology, National University of Singapore (NUS) in 1998 after postdoc training at Kiel University and industrial experience at Hoechst Marion Roussel (now Sanofil). Dr. Zhu was recruited as dean of Pharmacy and distinguished professor of pharmacology at Fudan University and served until Feb. 2016. Dr. Zhu published more than 180 peer-reviewed papers with more than 6800 citations and edited 6 books for his work. He is an editor-in-chief for Cardiovasc. Regenerative Med. and associate editor for J Alzheimer Diseases, Biosci. Reports academic editor for PLoS One and editorial board member of CNS Neuroscience & Therapeutics, Journal of Pharmacology and Drug Metabolism, Frontiers in Neurotrauma etc. Dr. Zhu is also editor-in-chief for the national text book of Pharmacology (7^th and 8^th edition [Chinese version] and 1^st edition [English version], People’s Medical Publishing House), Dr. Zhu was awarded ‘National Distinguished Young Scientist from Natural Science Foundation of China (NSFC) in 2008 and Chief Scientist of National Key Research Program (973) and Chief-PI for the National Platform of Drug Discovery in 2009. Dr. Zhu further received National Award for Innovative Research Work of the Returnees in 2009 from the State Council and Magnolia Award from Shanghai Government in 2010. Dr. Zhu was awarded 2011 Cheung Kong Chair Professorship by the Ministry of Education, China. In 2014, Dr. Zhu was awarded ‘Health China’ top 10 figures of the year. His research focuses on drug developments especially for heart and brain. Two novel compounds as drug candidates have been completed pre-clinical trials and are doing clinical trials now in US and China.